New Data Published in Journal Cell Show Robust Mobilization of .lst_arr{float:left;width:223px; height:503px; background-position:right 3px; background-repeat:no-repeat} Highly Engraftable Stem Cells in Mouse Models with Combination of .footer-nav a{font-size:12px; line-height:74px; color:#c0c0c0; padding: 0 5px; text-decoration:underline} .kwd_bloack{float:left; width:514px; margin-top:50px} GROβ and Plerixafor
Thursday, 07 December 2017 06:06
Dec. 7, 2017 17:00 UTC

New Data Published in Journal Cell Show Robust Mobilization of Highly Engraftable Stem Cells in Mouse Models with Combination of GROβ and Plerixafor

-- Publication from scientific collaboration lays foundation for Magenta Therapeutics data on .container{width:100%} GROβ and plerixafor in non-human primates to be presented at ASH annual meeting –

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the #logo{float:right;width:300px;padding:15px 0 0} use of .kwd_bloack h4{font-size:13px; line-height:18px; color:#ababab; padding-left: 4px; text-transform: uppercase; text-align: center;} curative bone marrow transplant for more patients, today announced the #logo p{text-align:right;clear:both;padding:4px 2px 0 0; color:#aeaeae;} publication of .kwd_bloack ul, .kwd_bloack ul li{float:left; text-align:center;width:514px;list-style:none} research led by Jonathan Hoggatt, Ph.D., assistant professor of .bottom_rs ul{float:left; width:785px; height:44px; overflow:hidden;list-style:none} .kwd_bloack ul{padding-top:9px} medicine at Harvard Medical School and the Massachusetts General Hospital (MGH) Cancer Center and Center for Transplantation Sciences, and a principal faculty member at Harvard Stem Cell Institute. Dr. Hoggatt is .leftblk{float:none; padding:0 5px} a scientific co-founder of .kwd_bloack ul li{line-height:30px} Magenta.

The research demonstrates that a single administration of .kwd_bloack ul li a{float:left;width:510px;text-decoration:underline; font-size:24px; font-weight:bold; color:#ffb047; display:block; word-wrap: break-word; padding: 10px 0} a chemokine, GROβ, in combination with plerixafor (also known as AMD3100) resulted in rapid mobilization of robust numbers of .bottom_bg{height:44px; background:#181818; margin-top:34px} hematopoietic stem cells (HSCs) from the #logo img{border:0 none;} bone marrow and into the .searchbox{float:right; width:351px; height:30px; padding-top:38px} blood, which were then harvested for transplant in mouse models. Notably, HSCs obtained with GROβ and plerixafor mobilization resulted in faster engraftment and higher donor chimerism, two important factors for the .srch-txt{float:left; width:242px; height:28px; font-size:16px; line-height:28px; background:url( 7px 5px no-repeat #fff; color:#414141; padding: 0 5px 0 30px; border:1px solid #6f6f6f; outline:none} success of .bottom_rs{width:960px; height:44px; overflow:hidden; margin:0 auto; position:relative} a transplant, compared to #footer-keys-bot{text-align:center;background:#373045; border-bottom:2px solid #776e99; line-height:28px; padding:20px 0; word-wrap:break-word; -webkit-box-shadow: 0px 1px 10px 0px rgba(0,0,0,0.75); cells obtained with the .srch-btn{float:right; width:66px; height:30px; font-size:13px; color:#303030; border:1px solid #6f6f6f; margin-left:4px; _border:none; * border:none; outlin:none; cursor:pointer; current mobilization standard of .bottom_rs h3{float:left; width:auto; font-size:13px; color:#ababab; line-height:44px; text-transform:capitalize;padding-left:8px} care, G-CSF. The article “Rapid Mobilization Reveals a Highly Engraftable Hematopoietic Stem Cell” was published in Cell online on December 7, 2017.

Now under exclusive license to -moz-box-shadow: 0px 1px 10px 0px rgba(0,0,0,0.75); Magenta from Harvard University’s Office of Technology Development, the technology described in this paper was co-developed by David Scadden, M.D., the Gerald and